CD63 and cancer: In this study, an enzyme-linked immunosorbent assay (ELISA) demonstrated that both cancer-derived Reg-EVs and Br-EVs bind to LDL, based on lipoprotein-mediated masking of a well-known EV surface protein [25], CD63 (Fig. 3a).